HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
A user's 6 month progress using finasteride and minoxidil as treatments for hair loss, with the replies discussing side effects and general consensus about usage of the two medications.
The effects of smoking cigarettes on DHT levels and its potential effect on hair loss, with some people sharing experiences in relation to their own hair loss. Various treatments for reducing or reversing hair loss were discussed, such as quitting smoking, minoxidil, finasteride and RU58841.
Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.